Literature DB >> 1390526

Detection of colour vision abnormalities in uncomplicated type 1 diabetic patients with angiographically normal retinas.

K J Hardy1, J Lipton, M O Scase, D H Foster, J H Scarpello.   

Abstract

Colour vision function was assessed in 38 non-complicated type 1 diabetic patients in whom fluorescein angiography was normal, and was compared with that in 36 age-matched, non-diabetic controls. All of the patients were healthy and none were taking medication except insulin. The eye examination, which was normal in every patient, included the Ishihara and City University tests, measurement of Snellen acuity, slit-lamp examination, tonometry, and fundal photography as well as fluorescein angiography. Colour discrimination ability was measured with the Farnsworth-Munsell 100-hue test. Mean (SE) 100-hue test error score for the diabetic group was 86.8 (8.1) compared with 28.2 (3.3) for controls, p<<0.001. There was no relation between colour vision abnormalities and diabetes duration (r = 0, p>0.05), blood glucose at the time the colour tests were performed (r = 0.4, p > 0.05), most recent glycated haemoglobin result (r = 0.3, p>0.05), or the mean of all previous glycated haemoglobin results (r = 0, p>0.05). It is concluded that colour discrimination may be abnormal in uncomplicated type 1 diabetic patients before the onset of retinopathy, and that colour discrimination losses in diabetes may not be of vascular aetiology.

Entities:  

Mesh:

Year:  1992        PMID: 1390526      PMCID: PMC504317          DOI: 10.1136/bjo.76.8.461

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  26 in total

1.  Modification by fluoangiography of colour vision in diabetic patients.

Authors:  M Fontana; G Verriest
Journal:  Bull Soc Belge Ophtalmol       Date:  1985

2.  Proposals for scoring and assessing the 100-Hue test.

Authors:  P R Kinnear
Journal:  Vision Res       Date:  1970-05       Impact factor: 1.886

3.  The effect of oral contraceptives on colour vision in diabetic women.

Authors:  R Lakowski; A Morton
Journal:  Can J Ophthalmol       Date:  1977-04       Impact factor: 1.882

4.  Color discrimination and accuracy of blood glucose self-monitoring in type I diabetic patients.

Authors:  P T Sawicki; L Karschny; V Stolpe; E Wolf; M Berger
Journal:  Diabetes Care       Date:  1991-02       Impact factor: 19.112

5.  Essential fatty acid treatment--effects on nerve conduction, polyol pathway and axonal transport in streptozotocin diabetic rats.

Authors:  D R Tomlinson; J P Robinson; A M Compton; P Keen
Journal:  Diabetologia       Date:  1989-09       Impact factor: 10.122

6.  The effect of gamma-linolenic acid on human diabetic peripheral neuropathy: a double-blind placebo-controlled trial.

Authors:  G A Jamal; H Carmichael
Journal:  Diabet Med       Date:  1990-05       Impact factor: 4.359

7.  Retinopathy in young-onset diabetic patients.

Authors:  R Klein; B E Klein; S E Moss; M D Davis; D L DeMets
Journal:  Diabetes Care       Date:  1985 Jul-Aug       Impact factor: 19.112

8.  Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy.

Authors:  C M Florkowski; B R Rowe; S Nightingale; T C Harvey; A H Barnett
Journal:  Diabetes       Date:  1991-01       Impact factor: 9.461

9.  Short-term effect of slit-lamp illumination and argon laser light on visual function of diabetic and non-diabetic subjects.

Authors:  I M Ghafour; W S Foulds; D Allan
Journal:  Br J Ophthalmol       Date:  1984-05       Impact factor: 4.638

10.  Essential fatty acids prevent slowed nerve conduction in streptozotocin diabetic rats.

Authors:  P O Julu
Journal:  J Diabet Complications       Date:  1988 Oct-Dec
View more
  31 in total

1.  Partial reversal of protan and tritan colour defects with inhaled oxygen in insulin dependent diabetic subjects.

Authors:  F M Dean; G B Arden; A Dornhorst
Journal:  Br J Ophthalmol       Date:  1997-01       Impact factor: 4.638

2.  Color vision in an elderly patient with protanopic genotype and successfully treated unilateral age-related macular degeneration.

Authors:  Takaaki Kitakawa; Takaaki Hayashi; Satoshi Tsuzuranuki; Akiko Kubo; Hiroshi Tsuneoka
Journal:  Int Ophthalmol       Date:  2011-11-11       Impact factor: 2.031

3.  Detecting ocular-visual function changes in diabetes.

Authors:  C A Westall
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

4.  Human photopic response to circulating glucose.

Authors:  W W Dawson; K Hazariwala; S Karges
Journal:  Doc Ophthalmol       Date:  2000-09       Impact factor: 2.379

5.  Color vision study to assess the impaired retina-brain cortex pathway in type 2 diabetes: a pilot study in Calabria (Southern Italy).

Authors:  Anna Piro; Antonio Tagarelli; Paolo Lagonia; Giuseppe Nicoletti; Aldo Quattrone
Journal:  Neurol Sci       Date:  2019-05-03       Impact factor: 3.307

6.  Effect of diabetes associated increases in lens optical density on colour discrimination in insulin dependent diabetes.

Authors:  K J Hardy; J H Scarpello; D H Foster; J D Moreland
Journal:  Br J Ophthalmol       Date:  1994-10       Impact factor: 4.638

7.  Extent of foveal tritanopia in diabetes mellitus.

Authors:  N Davies; A Morland
Journal:  Br J Ophthalmol       Date:  2003-06       Impact factor: 4.638

8.  Assessment of colour vision as a screening test for sight threatening diabetic retinopathy before loss of vision.

Authors:  G L Ong; L G Ripley; R S B Newsom; A G Casswell
Journal:  Br J Ophthalmol       Date:  2003-06       Impact factor: 4.638

9.  Effect of short term changes in blood glucose on visual pathway function in insulin dependent diabetes.

Authors:  K J Hardy; M O Scase; D H Foster; J H Scarpello
Journal:  Br J Ophthalmol       Date:  1995-01       Impact factor: 4.638

10.  Early visual deficits in streptozotocin-induced diabetic long evans rats.

Authors:  Moe H Aung; Moon K Kim; Darin E Olson; Peter M Thule; Machelle T Pardue
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-15       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.